Dr. Eggener’s research and clinical interests focus on improving the management and outcomes for patients with localized prostate cancer with specific emphasis on active surveillance, focal therapy and optimizing surgical outcomes. He has published extensively on prostate cancer with 75 peer-reviewed publications and multiple on PSA screening, surgery, prostate imaging, active surveillance or focal therapy for prostate cancer. He is on the editorial board of four journals, including Prostate Cancer and Prostatic Diseases.
Memorial Sloan-Kettering Cancer Center
New York
Urologic oncology fellowship
Northwestern Memorial Hospital
Chicago
General and urologic surgery internship and residency
Standford University School of Medicine
California
MD
Ex-vivo microscopic oncotesticular sperm extraction: step-by-step surgical technique at time of radical orchiectomy.
Ex-vivo microscopic oncotesticular sperm extraction: step-by-step surgical technique at time of radical orchiectomy. Fertil Steril. 2024 Feb 23.
PMID: 38403108
Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer.
Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer. Eur Urol. 2024 Jan 25.
PMID: 38278665
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 01; 42(10):1114-1123.
PMID: 38261983
Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen.
Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen. Am J Clin Pathol. 2024 Jan 04; 161(1):1-3.
PMID: 37639675
The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer.
The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer. J Natl Cancer Inst. 2023 11 08; 115(11):1364-1373.
PMID: 37285311
Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves cross-ancestry prediction.
Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves cross-ancestry prediction. medRxiv. 2023 Oct 30.
PMID: 37961155
Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer.
Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. J Clin Oncol. 2023 Dec 01; 41(34):5296-5305.
PMID: 37656935
Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen.
Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen. Am J Clin Pathol. 2023 Aug 28.
PMID: 37639675
Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial.
Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial. J Urol. 2023 10; 210(4):630-638.
PMID: 37384841
Improving reader accuracy and specificity with the addition of hybrid multidimensional-MRI to multiparametric-MRI in diagnosing clinically significant prostate cancers.
Improving reader accuracy and specificity with the addition of hybrid multidimensional-MRI to multiparametric-MRI in diagnosing clinically significant prostate cancers. Abdom Radiol (NY). 2023 10; 48(10):3216-3228.
PMID: 37358605